Healthcare

Nyrada Inc (ASX:NYR) shares traded at $0.48, up 9.09%, during the trading session on 26 October 2026, while the S&P/ASX 200 index (XJO) stood at 8,768.80, down 0.30% or 26.40 points, at 12:10 pm. Separately, the company's latest announcement on file is dated 19 …

Talius Group Limited (ASX:TAL) shares traded at $0.06, up 20.00%, during the trading session on 26 October 2026, while the S&P/ASX 200 index (XJO) stood at 8,768.80, down 0.30% or 26.40 points, at 12:10 pm. Talius provides technology-enabled care solutions to the aged and …

On 29 September 2026, Firebrick announced its decision to actively enter the US retail pharmacy market with Nasodine products. The move followed growth in online sales and the company’s attendance in August at the National Association of Chain Drug Stores retail trade expo in …

Field sales teams have finished training on both tests, such as their intended clinical uses and how clinicians and patients can access them. Proteomics International and Healius have also agreed joint sales and marketing plans to build clinician awareness, provide education and support appropriate …

The HARNESS-1 program evaluates RC220 with osimertinib in patients with EGFR-mutated non-small cell lung cancer. Ethics approval on 3 July 2026 enabled additional Australian trial sites to participate.

Following quarter-end, the company refined its strategy around immune modulation and inflammatory disease. RGT-CA91980 became the lead internally developed program, building on the development history of CimetrA and ArtemiC.

Two ALA-101 batches were manufactured and released for clinical use during September. The company stated that this supply was sufficient to complete dose escalation and begin dose expansion.